Cancer treatment may work better when the immune system gets both a clear target and help removing the brakes that hold its attack back. In mice, that combination slowed tumors, limited spread, and improved survival. Immune checkpoint inhibitors have moderate response rates in some cancers, and combining them with DNA tumor vaccines may improve cancer treatment.

Here, a vaccine and a treatment that blocks an immune brake were tested together. The vaccine alone or the antibody-making DNA alone produced weak tumor inhibition in mice. In comparison, the combined treatment produced stronger tumor growth inhibition and a survival rate of over 60% on day 45.

The approach uses DNA as instructions: it carries genes for a vaccine and an immune-checkpoint-blockade protein. A delivery system was used to improve delivery of those instructions. The treatment combined a DNA vaccine with DNA encoding an immune-checkpoint-blockade protein, bringing both components into one approach for these mice.

Together, this treatment caused enormous tumor regression and, through the delivery system, prevented lung metastasis in mice bearing OVA tumors. The DNA treatment was capable of encoding functional mouse antibodies against the immune-braking target, showing that the instructions could produce an antibody that worked as intended.

All mice receiving the antibody-making DNA had slower tumor growth than mice receiving the DNA vaccine alone. The combined treatment caused significant tumor regression, while body weight stayed steadily higher across groups. Survival differed sharply between groups.

About 60% of mice receiving the combined treatment survived for more than 45 days, compared with about 40% receiving another vaccine version with the antibody-making DNA and about 20% receiving the antibody-making DNA alone. The timeline makes the treatment sequence clear, while the separated growth and survival traces reveal how outcomes diverge after tumors appear.

The combined treatment activated more immune cells aimed at the chosen tumor target than the antibody-making DNA alone. In the lungs, control mice and mice receiving the vaccine without the delivery system had many signs of metastases, while the combined treatments had notably fewer lung nodules.

The combined treatment produced lung tissue that was almost normal. The combined treatment also raised the proportion of CD8-positive immune cells in blood by up to 45% and in the spleen by up to 27%. The proportion of another major T-cell group did not differ between treatments.

The results come with an important limit: DNA vaccines can produce weak immune responses, and blocking immune brakes can cause harmful reactions in some patients. Those issues still limit use in clinical care. Muscle was chosen because it is accessible, has a broad area for treatment, and contains many cells that can help present tumor targets to the immune system.

The strongest result came from combining the vaccine with the antibody-making DNA: survival improved and tumor growth fell. The proposed reason is that the vaccine stimulates T cells to recognize cancer targets, while the immune-brake treatment increases their activity and movement into tumors.

The combined treatment also increased several immune signals and raised levels of both major T-cell groups. But the researchers caution that these signals are only some of the factors affecting tumor size, so the tumor changes cannot be assigned completely to them.

The study suggests that a DNA vaccine and a DNA-made antibody can work together: one helps immune cells recognize the tumor, while the other helps those cells keep fighting. That could point toward a simpler cancer treatment strategy, though it remains a preclinical result.